Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: Results from a multicenter trial

López, Horacio Pérez; Li, Jim Z.; Balan, Dan A; Willke, Richard J.; Rittenhouse, B; Mozaffari, Essy; Vidal, Gabriela Pereira; Zitto, Teresa; Tang, Tom

doi:10.1016/s0149-2918(03)80173-x

Cited by 16 publications

(13 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two pharmacoeconomic studies investigated separately the medical resource used and direct medical costs for this trial. First, Lopez et al 17 studied the hospital resource use (mainly LOS) in 203 trial patients (97 treated with linezolid and 106 treated with teicoplanin) enrolled from Latin America. Patients treated with linezolid had a 1.6-day shorter adjusted LOS (P = 0.049) than those treated with teicoplanin.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacoeconomic Evaluation of Linezolid Versus Teicoplanin in Bacteremia by Gram-Positive Microorganisms*

et al. 2005

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Additionally, it has demonstrated greater effectiveness than other antibiotics in selected indications [12][13][14][15][16] and less consumption of healthcare resources 17,18 .…”

Section: Introductionmentioning

confidence: 99%

Pharmacoeconomic Evaluation of Linezolid Versus Teicoplanin in Bacteremia by Gram-Positive Microorganisms*

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Seventeen of these studies fulfilled the inclusion criteria and were included in the meta-analysis [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37]. (Figure 1) The main characteristics of these studies are presented in Table 1.…”

Section: Characteristics Of Eligible Studiesmentioning

confidence: 99%

Efficacy and safety of linezolid versus teicoplanin for the treatment of MRSA infections: a meta-analysis

Chen

et al. 2018

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of serious infections. Linezolid and teicoplanin are widely used in the treatment of infections caused by MRSA. However, the efficacy and safety of linezolid compared with teicoplanin remains controversial. The purpose of this study was to systematically review the efficacy and safety of linezolid versus teicoplanin for the treatment of MRSA infections. Methodology: A meta-analysis was performed on the published studies. Pooled relative risk (RR) and 95% confidence interval (95% CI) were calculated to determine whether there were significant differences between the linezolid group and the teicoplanin group on the efficacy and safety. Results: Seventeen studies were included, involving 2,040 patients. The results showed that linezolid was associated with better clinical cure rate (RR = 1.14, 95% CI = 1.08-1.21, p < 0.00001) and microbiological eradication rate (RR = 1.28, 95% CI = 1.18-1.39, p < 0.00001) compared with teicoplanin. There were no statistically significant differences between the two groups in the treatment of MRSA infections regarding the adverse events (RR = 1.15, 95% CI = 0.97-1.35, p = 0.10) and the mortality (RR = 0.85, 95% CI = 0.61-1.18, p = 0.33). Conclusions: The results suggest that linezolid may be a better choice for the treatment of patients with MRSA infections. However, our recommendation is that the decision about treating MRSA infections with linezolid or with teicoplanin should depend on local availability, patient population, dosage regimens, costs and safety, rather than presumed differences in efficacy.

show abstract

“…35,36 Streptogramins are a combination of quinupristin and dalfopristin (Synercid ® ). An oral streptogramin, pristinamycin in combination with doxycycline, is used in Europe to treat MRSA infections but is not available in the US.…”

Section: 1723-30mentioning

confidence: 99%

“…Unfortunately, the number of reports of resistance and therapeutic failure associated with linezolid has been increasing since 2005. 33,35,36,45 The Food and Drug Administration (FDA) updated the labeling for the antibiotic telithromycin (Ketek ® ) to improve its safe use of by patients; the changes include the removal of two of the three previously approved indications -acute bacterial sinusitis and acute bacterial exacerbations of chronic bronchitis -from the drug's label. The FDA approved "a boxed warning" that states that telithromycin is contraindicated in patients with myasthenia gravis.…”

Section: 1723-30mentioning

confidence: 99%

The determinants of the antibiotic resistance process

Espinosa¹

2009

IDR

View full text Add to dashboard Cite

Background:The use of antibiotic drugs triggers a complex interaction involving many biological, sociological, and psychological determinants. Resistance to antibiotics is a serious worldwide problem which is increasing and has implications for morbidity, mortality, and health care both in hospitals and in the community. Objectives: To analyze current research on the determinants of antibiotic resistance and comprehensively review the main factors in the process of resistance in order to aid our understanding and assessment of this problem. Methods: We conducted a MedLine search using the key words "determinants", "antibiotic", and "antibiotic resistance" to identify publications between 1995 and 2007 on the determinants of antibiotic resistance. Publications that did not address the determinants of antibiotic resistance were excluded. Results: The process and determinants of antibiotic resistance are described, beginning with the development of antibiotics, resistance and the mechanisms of resistance, sociocultural determinants of resistance, the consequences of antibiotic resistance, and alternative measures proposed to combat antibiotic resistance. Conclusions: Analysis of the published literature identifi ed the main determinants of antibiotic resistance as irrational use of antibiotics in humans and animal species, insuffi cient patient education when antibiotics are prescribed, lack of guidelines for treatment and control of infections, lack of scientifi c information for physicians on the rational use of antibiotics, and lack of offi cial government policy on the rational use of antibiotics in public and private hospitals.

show abstract

Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: Results from a multicenter trial

Cited by 16 publications

References 39 publications

Pharmacoeconomic Evaluation of Linezolid Versus Teicoplanin in Bacteremia by Gram-Positive Microorganisms*

Pharmacoeconomic Evaluation of Linezolid Versus Teicoplanin in Bacteremia by Gram-Positive Microorganisms*

Efficacy and safety of linezolid versus teicoplanin for the treatment of MRSA infections: a meta-analysis

The determinants of the antibiotic resistance process

Contact Info

Product

Resources

About